Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro
Figure 1
In vitro antiviral activity of silicone implants impregnated with ACV against HSV-2 and VZV. (a) Vero cells were grown to near-confluence and received either medium alone (“None”), acyclovir (0.22 μg/mL), or an acyclovir-containing silicone implant (MED-4050). One day later, wells were inoculated with either complete medium alone (“Mock”), 95 pfu of HSV-2 (G), or 95 pfu of HSV-2 (MS). Digital photos were taken 3 days after infection. This experiment was performed six times; representative wells are shown. Each implant was prepared by mixing polymer component A, polymer component B, and ACV in a 1 : 1 : 1 ratio as described in Section 2. (b) MRC-5 cells were grown to near-confluence and received either medium alone (“None”), acyclovir (10 μg/mL), or an acyclovir-containing silicone implant (MED-4050). Two days later, wells were inoculated with either buffer alone (“Mock”) or 150 pfu of VZV. Digital photos were taken 10 days after infection. This experiment was performed three times; representative wells are shown. Each implant was prepared by mixing polymer component A, polymer component B, and ACV in a 1 : 1 : 1 ratio as described in Section 2.
